Skip to main content

Table 1 Baseline characteristics of the study population

From: Long-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center, 80-week retrospective study in Japan

Parameters Total
N = 87
HD
n = 62
VS. PD (HYB)
n = 25 (7)
Age (years) 61.9 ± 12.5 65.1 ± 11.9   54.0 ± 10.4
Gender [male/female (male %)] 49/38 (56.3) 37/25 (59.7)   12/13 (48.0)
Duration of dialysis (years) 5.81 ± 5.90 6.38 ± 6.56   4.42 ± 3.51
Cause of ESRD (DM %) 40 (46.0) 30 (48.4)   10 (40.0)
Laboratory data at start
 Hemoglobin (g/dL) 10.0 ± 0.80 10.1 ± 0.67   9.9 ± 1.05
 Transferrin saturation (%) 19.1 ± 8.86 17.7 ± 8.34   22.5 ± 9.34
 Serum ferritin (ng/dL) 52.1 ± 43.3 45.3 ± 28.1   69.1 ± 63.0
 Serum phosphate (mg/dL) 6.13 ± 1.15 6.21 ± 1.19   5.92 ± 1.07
 Corrected serum calcium (mg/dL) 9.24 ± 0.79 9.16 ± 0.77   9.45 ± 0.82
 Intact PTH (pg/dL) 261.1 ± 204.7 228.6 ± 146.3   341.9 ± 293.6
 Albumin (g/dL) 3.65 ± 0.38 3.72 ± 0.34   3.48 ± 0.44
 C-reactive protein (mg/dL) 0.30 ± 0.40 0.32 ± 0.38   0.27 ± 0.43
Concomitant drugs at start
 Average DA dosage (μg/week) 34.4 ± 24.8 35.1 ± 27.1   32.5 ± 18.1
aIV or oral iron preparations, N (%) 34 (39.1) 25 (40.3)   9 (36.0)
 Calcium carbonate, N (%) 53 (60.9) 42 (67.7)   11 (44.0)
 Sevelamer hydrochloride, N (%) 8 (9.2) 3 (4.8)   5 (20.0)
 Lanthanum carbonate, N (%) 37 (42.5) 27 (43.5)   10 (40.0)
 Cinacalcet, N (%) 20 (23.0) 14 (22.6)   6 (24.0)
  1. Data are presented as means ± standard deviation
  2. HD hemodialysis, PD peritoneal dialysis, HYB combination therapy with PD and HD, ESRD end-stage renal disease, DM diabetes mellitus, PTH parathormone, DA darbepoetin alpha
  3. aIV iron, intravenous saccharated iron oxide; oral iron, ferrous citrate